Articles tagged with: Velcade

News»

[ by | Mar 5, 2010 12:53 pm | Comments Off ]
Study Documents The Impact Of Age At Diagnosis On Myeloma Patient Survival

The survival time of a multiple myeloma patient is strongly dependent on the patient’s age at diagnosis, according to a recent study published in the Journal of Clinical Oncology. The study, which evaluated the impact of age on disease outcome, compared the survival time (from diagnosis) between patients in different age groups and treatment regimens. Researchers also compared the life spans for patients with myeloma versus patients without myeloma.

Following diagnosis with multiple myeloma, the average survival time varies based on the type of treatment that a patient receives. For …

Read the full story »

News»

[ by | Mar 3, 2010 3:31 pm | Comments Off ]
Genetic Risk Factors And Treatment History May Predict Response In Patients With Relapsed/Refractory Myeloma

A new study published in the journal Leukemia determined that when treated with Revlimid (lenalidomide) and dexamethasone (Decadron), relapsed and refractory myeloma patients with genetic risk factors experience lower response rates and shorter progression-free and overall survival durations.

Researchers also discovered that prior treatment with thalidomide (Thalomid) was associated with a decreased progression-free and overall survival.

Multiple myeloma patients with the chromosomal abnormalities del(13), t(4;14) or del(17p) are associated with a poorer prognosis in response to traditional chemotherapy. However, new drug and treatment options have the potential …

Read the full story »

News»

[ by | Feb 23, 2010 3:32 pm | 9 Comments ]
The Top Myeloma Research Of 2009

The year 2009 brought a lot of new and exciting advancements in the field of multiple myeloma. Over the course of 2009, The Myeloma Beacon covered more than 100 important myeloma-related studies.

To highlight the most important of these studies, the Myeloma Beacon surveyed leading physicians and researchers in the field. These physicians and researchers were asked to name the three peer reviewed journal articles published in 2009 and the three conference abstracts from 2009 that have the most important findings or implications relating to multiple myeloma.

The top …

Read the full story »

News, Resources»

[ by | Feb 17, 2010 12:59 pm | 11 Comments ]
Curcumin And Multiple Myeloma: Preclinical And Early Clinical Studies Are Promising; Still Awaiting More Clinical Evidence

Curcumin has been garnering increased attention as a potential anticancer treatment. It is the major active compound in turmeric, a popular Indian spice made from the rhizomes, or underground stalks, of a plant in the ginger family.

In multiple myeloma and the precursor condition monoclonal gammopathy of undetermined significance (MGUS), cell culture studies and one animal study have shown that curcumin can kill cancer cells and prevent them from multiplying. The Beacon also found two early-stage clinical trials studying curcumin’s effects in people with multiple …

Read the full story »

News»

[ by | Feb 2, 2010 3:13 pm | 3 Comments ]
Velcade-Doxil-Dexamethasone Regimen Followed By Post-Transplant Revlimid May Be A Highly Effective Treatment For Newly Diagnosed Myeloma Patients

A combination regimen of Velcade (bortezomib), Doxil (pegylated liposomal doxorubicin), and dexamethasone (Decadron), known as the VDD regimen, followed by Revlimid (lenalidomide) after autologous stem cell transplantation (ASCT) is an effective therapy for untreated multiple myeloma patients, according to a study recently published in the Journal of Clinical Oncology.

Velcade is a highly active therapeutic agent in multiple myeloma patients. It suppresses tumor growth by inhibiting the enzymes that break down critical proteins in cancerous cells. Although Velcade is approved as a single agent, previous studies …

Read the full story »